The above findings establish that TIMM23 depletion, achieved through either knockdown (shRNA) or KO (CRISPR/Cas-9) strategies, exerted pronounced anti-cancer effects within both primary and immortalized NSCLC cells. The gene discussed is TIMM23; the disease is non-small cell lung carcinoma.